Association of height, BMI, and smoking status with prostate cancer risk before and after the introduction of PSA testing in Sweden
(2025) In Scientific Reports 15(1).- Abstract
- Prostate cancer (PCa) incidence has steadily increased in Sweden, more steeply in the mid-1990s caused by increased opportunistic prostate-specific antigen (PSA) testing. Tallness, normal weight, and non-smoking are associated with more PSA testing, which increases detection of low-risk and localised PCa. We investigated time trends of height, body mass index (BMI), and smoking with PCa risk in 171,889 men in Sweden aged 50–64 years at baseline, who were linked to nationwide cancer registers during follow-up. Cox regression determined the association of these factors assessed before 1980, 1980–1994, and 1995–2004 with PCa risk. During 15 follow-up years, 8,049 men were diagnosed with PCa. The association of height with PCa was weakly... (More) 
- Prostate cancer (PCa) incidence has steadily increased in Sweden, more steeply in the mid-1990s caused by increased opportunistic prostate-specific antigen (PSA) testing. Tallness, normal weight, and non-smoking are associated with more PSA testing, which increases detection of low-risk and localised PCa. We investigated time trends of height, body mass index (BMI), and smoking with PCa risk in 171,889 men in Sweden aged 50–64 years at baseline, who were linked to nationwide cancer registers during follow-up. Cox regression determined the association of these factors assessed before 1980, 1980–1994, and 1995–2004 with PCa risk. During 15 follow-up years, 8,049 men were diagnosed with PCa. The association of height with PCa was weakly positive across all calendar periods. For obesity (BMI ≥30 kg/m2) vs. normal weight (BMI 18.5–24.9 kg/m2) and current vs. never smoking, the associations changed from null before 1980 (HR 1.03, 95% CI 0.86–1.23, and 1.11, 95% CI 0.97–1.27) to negative in 1995–2004 (HR 0.83, 95% CI 0.74–0.93, and 0.86, 95% CI 0.79–0.93; pinteraction between periods = 0.05 and 0.001). In men with clinical characteristics available, height was positively associated with both aggressive and non-aggressive PCa whilst obesity and smoking showed negative associations only with non-aggressive PCa. These findings likely reflect differences in PSA testing by BMI and smoking habits and contribute important knowledge for etiological studies of PCa. (Less)
- author
- organization
- publishing date
- 2025-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Body height, Body mass index, Prostate-specific antigen, Prostatic neoplasms, Smoking
- in
- Scientific Reports
- volume
- 15
- issue
- 1
- article number
- 20290
- publisher
- Nature Publishing Group
- external identifiers
- 
                - pmid:40562803
- scopus:105008963299
 
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-025-06548-y
- language
- English
- LU publication?
- yes
- id
- 7e97bf72-4053-4316-84d3-659d3197c1a2
- date added to LUP
- 2025-10-27 14:18:54
- date last changed
- 2025-10-28 15:39:40
@article{7e97bf72-4053-4316-84d3-659d3197c1a2,
  abstract     = {{<p>Prostate cancer (PCa) incidence has steadily increased in Sweden, more steeply in the mid-1990s caused by increased opportunistic prostate-specific antigen (PSA) testing. Tallness, normal weight, and non-smoking are associated with more PSA testing, which increases detection of low-risk and localised PCa. We investigated time trends of height, body mass index (BMI), and smoking with PCa risk in 171,889 men in Sweden aged 50–64 years at baseline, who were linked to nationwide cancer registers during follow-up. Cox regression determined the association of these factors assessed before 1980, 1980–1994, and 1995–2004 with PCa risk. During 15 follow-up years, 8,049 men were diagnosed with PCa. The association of height with PCa was weakly positive across all calendar periods. For obesity (BMI ≥30 kg/m<sup>2</sup>) vs. normal weight (BMI 18.5–24.9 kg/m<sup>2</sup>) and current vs. never smoking, the associations changed from null before 1980 (HR 1.03, 95% CI 0.86–1.23, and 1.11, 95% CI 0.97–1.27) to negative in 1995–2004 (HR 0.83, 95% CI 0.74–0.93, and 0.86, 95% CI 0.79–0.93; p<sub>interaction</sub> between periods = 0.05 and 0.001). In men with clinical characteristics available, height was positively associated with both aggressive and non-aggressive PCa whilst obesity and smoking showed negative associations only with non-aggressive PCa. These findings likely reflect differences in PSA testing by BMI and smoking habits and contribute important knowledge for etiological studies of PCa.</p>}},
  author       = {{Mboya, Innocent B. and Fritz, Josef and Scilipoti, Pietro and Häggström, Christel and da Silva, Marisa and Sun, Ming and Wahlström, Jens and Oskarsson, Viktor and Michaëlsson, Karl and Leppert, Jerzy and Chabok, Abbas and Magnusson, Patrik K.E. and Lagerros, Ylva Trolle and Bonn, Stephanie E. and Hedman, Linnea and Stattin, Pär and Stocks, Tanja}},
  issn         = {{2045-2322}},
  keywords     = {{Body height; Body mass index; Prostate-specific antigen; Prostatic neoplasms; Smoking}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{Association of height, BMI, and smoking status with prostate cancer risk before and after the introduction of PSA testing in Sweden}},
  url          = {{http://dx.doi.org/10.1038/s41598-025-06548-y}},
  doi          = {{10.1038/s41598-025-06548-y}},
  volume       = {{15}},
  year         = {{2025}},
}
